Enhancement of ciprofloxacin activity by incorporating it in solid lipid nanoparticles

Alarifi, Saqer; Massadeh, Salam; Al-Agamy, Mohammed; Aamery, Manal A.l.; Bekairy, Abdulkareem Al; Yassin, Alaa Eldeen B.

doi:10.4314/tjpr.v19i5.1

Cited by 13 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observed higher cumulative % release with F9, containing a combination of Dynasan 114 and Imwitor 308, is in agreement with the results reported by Alarifi et al [65] for the release of ciprofloxacin from SLN composed of stearic acid/Imwitor 900 or Dynasan 118 combinations. The significant increase in the cumulative CXB% release when using Cremophor EL as a surfactant is in agreement with Kiss et al [66], who concluded that Cremophor EL causes a reduction in the melting point of lipid mixture, resulting in a reduction in their crystallinity index.…”

Section: Discussionsupporting

confidence: 92%

Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity

et al. 2022

View full text Add to dashboard Cite

This work aimed to optimize a celecoxib (CXB)-loaded solid lipid nanoparticles (SLN) colon delivery system for the enhancement of anticancer activity. An ultrasonic melt-emulsification method was employed in this work for the preparation of SLN. The physical attributes were characterized for their particle sizes, charges, morphology, and entrapment efficiency (%EE), in addition to DSC and FTIR. The in vitro drug release profiles were evaluated, and the anticancer activity was examined utilizing an MTT assay in three cancer cell lines: the colon cancer HT29, medulloblastoma Daoy, and hepatocellular carcinoma HepG2 cells. All of the prepared SLN formulations had nanoscale particle sizes ranging from 238 nm to 757 nm. High zeta-potential values (mv) within −30 s mv were reported. The %EE was in the range 86.76–96.6%. The amorphous nature of the SLN-entrapped CXB was confirmed from SLN DSC thermograms. The in vitro release profile revealed a slow constant rate of release with no burst release, which is unusual for SLN. Both the F9 and F14 demonstrated almost complete CXB release within 24 h, with only 25% completed within the first 5 h. F9 caused a significant percentage of cell death in the three cancer cell lines tested after 24 h of incubation and maintained this effect for 72 h. The prepared CXB-loaded SLN exhibited unique properties such as slow release with no burst and a high %EE. The anticancer activity of one formulation was extremely significant in all tested cancer cell lines at all incubation times, which is very promising.

show abstract

Section: Discussionsupporting

confidence: 92%

Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The lipids used in the ultrasonication and high-speed homogenization methods include glyceryl behenate and tri-behenate (Compritol), glycerol monostearate (GMS), tristearin glyceride, and stearic acid [ 21 ]. At the same time, the surfactants that can be used are Poloxamer 188, Lecithin, and Tween [ 79 , 87 ]. The synthesis of SLNs using the ultrasonication method begins by dissolving the active compound to be encapsulated with melted lipid, and then the mixture is heated to 10 °C above the lipid melting point.…”

Section: Fabrication Methods For Slnsmentioning

confidence: 99%

“…The synthesis of SLNs using the ultrasonication method begins by dissolving the active compound to be encapsulated with melted lipid, and then the mixture is heated to 10 °C above the lipid melting point. The mixture of lipids and active compounds is then mixed into a liquid phase containing preheated surfactants and cosurfactants; the mixture is then heated to the same temperature as before and stirred slowly until a pre-emulsion is formed [ 52 , 87 ].…”

Section: Fabrication Methods For Slnsmentioning

confidence: 99%

Solid Lipid Nanoparticles: Review of the Current Research on Encapsulation and Delivery Systems for Active and Antioxidant Compounds

2023

View full text Add to dashboard Cite

Various active compounds are easily damaged, so they need protection and must be easily absorbed and targeted. This problem can be overcome by encapsulating in the form of solid lipid nanoparticles (SLNs). Initially, SLNs were widely used to encapsulate hydrophobic (non-polar) active compounds because of their matched affinity and interactions. Currently, SLNs are being widely used for the encapsulation of hydrophilic (polar) and semipolar active compounds, but there are challenges, including increasing their entrapment efficiency. This review provides information on current research on SLNs for encapsulation and delivery systems for active and antioxidant compounds, which includes various synthesis methods and applications of SLNs in various fields of utilization. SLNs can be developed starting from the selection of solid lipid matrices, emulsifiers/surfactants, types of active compounds or antioxidants, synthesis methods, and their applications or utilization. The type of lipid used determines crystal formation, control of active compound release, and encapsulation efficiency. Various methods can be used in the SLN fabrication of active compounds and hydrophilic/hydrophobic antioxidants, which have advantages and disadvantages. Fabrication design, which includes the selection of lipid matrices, surfactants, and fabrication methods, determines the characteristics of SLNs. High-shear homogenization combined with ultrasonication is the recommended method and has been widely used because of the ease of preparation and good results. Appropriate fabrication design can produce SLNs with stable active compounds and antioxidants that become suitable encapsulation systems for various applications or uses.

show abstract

“…The outcomes of the pharmacodynamic investigation show that both topical and oral Pi have a suitable response compared to for example oral chloroquine suspension. Alarifi et al [ 156 ] designed formulations of ciprofloxacin (CIP) into SLNs as a means to improve its biopharmaceutical and biochemical properties and its anti-inflammatory properties. The results of the evaluation showed that encapsulation of CIP in SLNs increased its antimicrobial and anti-inflammatory activities in vitro which could significantly improve a treatment by reducing dose-dependent side effects and increasing the range of protective activities.…”

Section: Nanomaterials For the Treatment Of Inflammatory Arthritismentioning

confidence: 99%

Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis

Hosseinikhah

Barani

Rahdar

et al. 2021

IJMS

View full text Add to dashboard Cite

Nanomaterials have received increasing attention due to their unique chemical and physical properties for the treatment of rheumatoid arthritis (RA), the most common complex multifactorial joint-associated autoimmune inflammatory disorder. RA is characterized by an inflammation of the synovium with increased production of proinflammatory cytokines (IL-1, IL-6, IL-8, and IL-10) and by the destruction of the articular cartilage and bone, and it is associated with the development of cardiovascular disorders such as heart attack and stroke. While a number of imaging tools allow for the monitoring and diagnosis of inflammatory arthritis, and despite ongoing work to enhance their sensitivity and precision, the proper assessment of RA remains difficult particularly in the early stages of the disease. Our goal here is to describe the benefits of applying various nanomaterials as next-generation RA imaging and detection tools using contrast agents and nanosensors and as improved drug delivery systems for the effective treatment of the disease.

show abstract

Enhancement of ciprofloxacin activity by incorporating it in solid lipid nanoparticles

Cited by 13 publications

References 23 publications

Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity

Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity

Solid Lipid Nanoparticles: Review of the Current Research on Encapsulation and Delivery Systems for Active and Antioxidant Compounds

Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis

Contact Info

Product

Resources

About